New hope for advanced kidney cancer patients after immunotherapy fails

NCT ID NCT07011719

Recruiting now Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a new drug called casdatifan to an existing cancer drug (cabozantinib) works better than cabozantinib alone for people with advanced kidney cancer. It's for patients whose cancer has continued to grow despite previous immunotherapy treatment. The main goal is to see if the new combination can keep the cancer from getting worse for a longer period of time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Barts Hospital
RECRUITING

London, United Kingdom
City Of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
City of Hope - Chicago Cancer Center
RECRUITING

Zion, Illinois, 60099, United States
City of Hope - Phoenix Cancer Center
RECRUITING

Goodyear, Arizona, 85338, United States
City of Hope Cancer Center Atlanta
RECRUITING

Newnan, Georgia, 30265, United States
Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44106, United States
Compass Oncology, OR
RECRUITING

Portland, Oregon, 97212, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Emory University - Atlanta
RECRUITING

Atlanta, Georgia, 30322, United States
Indiana University Melvin and Bren Simon Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Institut Gustave Roussy
RECRUITING

Villejuif, France
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Norton Cancer Institute PARENT
RECRUITING

Louisville, Kentucky, 40207, United States
Piedmont Cancer Institute OneOncology
RECRUITING

Atlanta, Georgia, 30318, United States
Pratia MCM Krakow
RECRUITING

Krakow, Poland
Radboudumc
RECRUITING

Nijmegen, Netherlands
S.C Oncomed S.R.L
RECRUITING

Timișoara, Romania
S.C. Sigmedical Services SRL
RECRUITING

Suceava, Romania
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea
Texas Tech University Health Science Center
RECRUITING

Lubbock, Texas, 79430, United States
The University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
UCLA Hematology Oncology - 100 Med Plaza
RECRUITING

Los Angeles, California, 90095, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of California San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92103, United States
University of California San Diego Moores Cancer Center
RECRUITING

San Diego, California, 92103, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14642, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Yale University
RECRUITING

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED CLEAR CELL RENAL CELL CARCINOMA METASTATIC CLEAR CELL RENAL CELL CARCINOMA